Going the distance: Are we losing patients along the multiple myeloma treatment pathway?
Author:
Funder
Amgen (Europe) GmbH
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference39 articles.
1. New agents in multiple myeloma: an examination of safety profiles;Bringhen;Clin. Lymphoma Myeloma Leuk.,2017
2. Drug policy for an aging population—the European Medicines Agency’s geriatric medicines strategy;Cerreta;N. Engl. J. Med.,2012
3. A question of class: treatment options for patients with relapsed and/or refractory multiple myeloma;Cook;Crit. Rev. Oncol. Hematol.,2018
4. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma;Dimopoulos;N. Engl. J. Med.,2007
5. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study;Dimopoulos;Lancet Oncol.,2016
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR);Cancers;2023-02-02
2. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial;Blood Cancer Journal;2022-01-24
3. Menaquinone-7: Wide Ranging Physiological Relevance in Muscle and Nerve Health;Vitamin K - Recent Advances, New Perspectives and Applications for Human Health [Working Title];2021-09-08
4. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial;Journal of Clinical Oncology;2020-12-01
5. Hunting down the dominating subclone of cancer stem cells as a potential new therapeutic target in multiple myeloma: An artificial intelligence perspective;World Journal of Stem Cells;2020-08-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3